Elite Pharmaceuticals, Inc. (ELTP)
| Market Cap | 310.22M -47.1% |
| Revenue (ttm) | 141.01M +33.7% |
| Net Income | 56.67M |
| EPS | 0.04 |
| Shares Out | 1.08B |
| PE Ratio | 6.56 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,930,028 |
| Open | 0.2995 |
| Previous Close | 0.2880 |
| Day's Range | 0.2874 - 0.2995 |
| 52-Week Range | 0.2720 - 0.7400 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules to treat bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipi... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Elite Pharmaceuticals Earnings Call Transcript: Q1 2027
Quarterly revenue and profit remained steady, with increased market share for key products despite lower year-over-year revenue due to last year's exceptional Vyvanse launch. The robust pipeline, strong cash position, and potential tariff changes support a positive outlook.
Elite Pharmaceuticals Quarterly report: Q1 2027
Elite Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 14, 2026.
Elite Pharmaceuticals Earnings release: Q1 2027
Elite Pharmaceuticals released its Q1 2027 earnings on August 14, 2026, summarizing the period's financial results.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Financials for First Quarter of Fiscal Year 2027 Ended June 30, 2026 will be released on Thursday, August 13, 2026 Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, In...
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, t...
Elite Pharmaceuticals Earnings Call Transcript: Q4 2026
Record revenues and profits were achieved, driven by new product launches, expanded manufacturing, and strong market share in key generics. The company maintains a robust pipeline, low debt, and is evaluating M&A and Nasdaq uplisting while continuing internal growth.
Elite Pharmaceuticals Annual report: Q4 2026
Elite Pharmaceuticals has published its Q4 2026 annual report on June 30, 2026.
Elite Pharmaceuticals Earnings release: Q4 2026
Elite Pharmaceuticals released its Q4 2026 earnings on June 30, 2026, summarizing the period's financial results.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - June 29, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a special...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Financials for Fiscal Year 2026 Ended March 31, 2026 will be released on Monday, June 29, 2026 Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Eli...
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Northvale, New Jersey--(Newsfile Corp. - June 15, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufactu...
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufactur...
Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets
Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, to...
Elite Pharmaceuticals Earnings Call Transcript: Q3 2026
Record Q3 and nine-month results with revenue and profit more than doubling year-over-year, driven by strong market share in key generics and new product launches. Outlook remains positive with further launches and R&D investment planned.
Elite Pharmaceuticals Earnings release: Q3 2026
Elite Pharmaceuticals released its Q3 2026 earnings on February 18, 2026, summarizing the period's financial results.
Elite Pharmaceuticals Quarterly report: Q3 2026
Elite Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 18, 2026.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Conference Call Scheduled for Wednesday, February 18 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"),...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Financials for Third Quarter of Fiscal Year 2026 Ended December 31, 2025 will be released on Tuesday, February 17, 2026 Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceutic...
Elite Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 FY2026 revenue nearly doubled year-over-year, driven by strong lisdexamfetamine sales and expanding market share in key products. Margins declined due to competition and one-time costs, but cash flow and balance sheet strength improved. M&A remains a strategic focus.
Elite Pharmaceuticals Earnings release: Q2 2026
Elite Pharmaceuticals released its Q2 2026 earnings on November 17, 2025, summarizing the period's financial results.
Elite Pharmaceuticals Quarterly report: Q2 2026
Elite Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 17, 2025.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Conference Call Scheduled for Monday, November 17 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a ...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025 Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuti...
Elite Pharmaceuticals Earnings Call Transcript: Q1 2026
Record quarterly revenue and profit growth driven by Lisdex and Elite label products, with strong cash flow and working capital. Margins are expected to decline as competition intensifies, but market share and product pipeline remain robust.